| Date Filed | Type | Description |
| 08/21/2023 |
4
| Bailey Jeffrey Allen (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 17,913 restricted stock units
@ $0
Granted 28,959 options to buy
@ $9.49, valued at
$274.8k
|
|
| 08/21/2023 |
3
| Bailey Jeffrey Allen (Director) has filed a Form 3 on Aurinia Pharmaceuticals Inc. |
| 08/21/2023 |
4
| Smith Karen L. (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 17,913 restricted stock units
@ $0
Granted 28,959 options to buy
@ $9.49, valued at
$274.8k
|
|
| 08/21/2023 |
3
| Smith Karen L. (Director) has filed a Form 3 on Aurinia Pharmaceuticals Inc. |
| 05/23/2023 |
4
| Balakrishnan Brinda (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 9,310 shares
@ $0
Exercised 8,733 restricted stock units
@ $0
Granted 15,234 options to buy
@ $10.74, valued at
$163.6k
|
|
| 05/23/2023 |
4
| Jayne David R.W. (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 9,310 shares
@ $0
Sold 8,733 shares
@ $11.26, valued at
$98.3k
Exercised 8,733 restricted stock units
@ $0
Granted 15,234 options to buy
@ $10.74, valued at
$163.6k
|
|
| 05/23/2023 |
4
| Hagan Joseph P (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Sold 272 shares
@ $10.58, valued at
$2.9k
Exercised 8,733 restricted stock units
@ $0 |
|
| 05/23/2023 |
4
| Billen Daniel (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 9,310 shares
@ $0
Sold 4,650 shares
@ $11.26, valued at
$52.4k
Exercised 8,733 restricted stock units
@ $0
Granted 15,234 options to buy
@ $10.74, valued at
$163.6k
|
|
| 05/23/2023 |
4
| MILNE GEORGE M JR (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Exercised 8,733 restricted stock units
@ $0 |
|
| 05/23/2023 |
4
| MacKay-Dunn R. Hector (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 9,310 shares
@ $0
Sold 4,818 shares
@ $11.26, valued at
$54.3k
Exercised 8,733 restricted stock units
@ $0
Granted 15,234 options to buy
@ $10.74, valued at
$163.6k
|
|
| 05/23/2023 |
4
| Leversage Jill (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 9,310 shares
@ $0
Sold 4,815 shares
@ $11.26, valued at
$54.2k
Exercised 8,733 restricted stock units
@ $0
Granted 15,234 options to buy
@ $10.74, valued at
$163.6k
|
|
| 03/06/2023 |
4
| MILNE GEORGE M JR (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Bought 20,000 shares
@ $8.9142, valued at
$178.3k
|
|
| 03/06/2023 |
4
| Donley Matthew Maxwell (EVP, Ops & Strategy) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 271,134 shares
@ $0 |
|
| 03/06/2023 |
4
| Miller Joseph M (CFO) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 229,421 shares
@ $0
Sold 11,296 shares
@ $8.94, valued at
$101k
|
|
| 03/06/2023 |
4
| Robertson Stephen P. (EVP, General Counsel) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 204,810 shares
@ $0
Sold 19,402 shares
@ $8.94, valued at
$173.5k
|
|
| 03/06/2023 |
4
| Martin Michael Robert (Chief Business Officer) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 107,202 shares
@ $0 |
|
| 03/06/2023 |
4
| Habig Scott Michael (Chief Commercial Officer) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 170,188 shares
@ $0 |
|
| 03/06/2023 |
4
| Knappertz Volker (EVP, Research and Development) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 191,462 shares
@ $0 |
|
| 03/06/2023 |
4
| Greenleaf Peter (CEO) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 667,407 shares
@ $0
Sold 32,750 shares
@ $8.94, valued at
$292.8k
|
|
| 11/23/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/14/2022 |
4
| Habig Scott Michael (Chief Commercial Officer) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Bought 5,000 shares
@ $5.015, valued at
$25.1k
|
|
| 11/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/01/2022 |
4
| Knappertz Volker (EVP, Research and Development) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 256,892 options to buy
@ $8.18, valued at
$2.1M
Granted 152,812 restricted stock units
@ $0 |
|
| 08/01/2022 |
4
| Habig Scott Michael (Chief Commercial Officer) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 231,203 options to buy
@ $8.18, valued at
$1.9M
Granted 137,531 restricted stock units
@ $0 |
|
| 07/19/2022 |
3
| Knappertz Volker (EVP, Research and Development) has filed a Form 3 on Aurinia Pharmaceuticals Inc. |
| 07/19/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/11/2022 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/20/2022 |
4
| Balakrishnan Brinda (Director) has filed a Form 4 on Aurinia Pharmaceuticals Inc.|
Txns:
| Granted 8,733 restricted stock units
@ $0
Granted 14,612 options to buy
@ $11.45, valued at
$167.3k
|
|
|